Voyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Below 50-Day Moving Average – Should You Sell?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.69 and traded as low as $3.15. Voyager Therapeutics shares last traded at $3.16, with a volume of 904,679 shares.

Analysts Set New Price Targets

VYGR has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Wednesday, April 15th. Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Truist Financial upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

The company has a market capitalization of $190.93 million, a PE ratio of -1.60 and a beta of 1.27. The company’s 50-day moving average is $3.69 and its 200 day moving average is $3.85.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The business had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. On average, analysts forecast that Voyager Therapeutics, Inc. will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VYGR. Wexford Capital LP bought a new position in Voyager Therapeutics in the 3rd quarter valued at approximately $42,000. ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth $44,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth $45,000. Coldstream Capital Management Inc. purchased a new position in shares of Voyager Therapeutics in the third quarter worth $55,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Voyager Therapeutics by 42,410.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after purchasing an additional 15,692 shares during the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.